Composite Lipid Nanoparticles for Nucleic Acid Stability and Cellular Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Efficient and targeted delivery of biologically active substances such as nucleic acids to cells is challenging due to their instability and low cellular permeability, with existing lipid nanoparticle (LNP) formulations often accumulating primarily in liver tissue, limiting their clinical utility.
Innovation Solution
A novel lipid compound and lipid nanoparticle composition with high encapsulation efficiency and low toxicity, designed for extrahepatic delivery, incorporating specific lipid components and preparation methods to enhance targeted delivery of therapeutic and prophylactic agents, including nucleic acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional LNP formulations are used, then delivery efficiency to liver tissue is improved, but delivery capability to extrahepatic tissues is limited
Solution Approach 1:
The patent modifies specific properties of lipid components (particularly the ionizable lipid structure with specific R1-R6 substituents) to create localized functional differences that enable tissue-specific delivery. The chemical structure modifications at specific positions (R1-R6 groups) create local quality changes in the LNP that direct accumulation to extrahepatic tissues while maintaining overall delivery efficiency
Solution Approach 2:
The patent systematically changes chemical parameters of the lipid components, specifically the structure of the ionizable lipid with varying R1-R6 substituents (alkyl groups of different lengths and positions). These parameter changes in the molecular structure directly influence the biodistribution and tissue accumulation patterns, enabling transition from liver-specific to extrahepatic delivery
2Ease of operation
If nucleic acids are delivered directly to cells, then cellular permeability is limited, but stability is compromised
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary carrier system. The LNP composition (including ionizable lipids, phospholipids, cholesterol, and PEG-lipids) acts as a mediator that protects nucleic acids from degradation while facilitating their entry into cells. The lipid coating provides stability during circulation and enables cellular uptake through endosomal escape mechanisms
Solution Approach 2:
The patent creates a composite delivery system combining nucleic acids with multiple lipid components. The composite LNP structure integrates ionizable lipids (for endosomal escape), phospholipids (for membrane interaction), cholesterol (for structural stability), and PEG-lipids (for steric stabilization). This composite material simultaneously provides protection and delivery capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves effective delivery of nucleic acids to cells with high expression and safety, expanding the clinical utility of LNPs beyond liver tissue.
Implementation Method 1
The OnpattroTM formulation accumulates primarily in liver tissue
Data Source
AI summary
The present application disclosed a compound of formula (I) and a salt and a stereoisomer thereof, wherein each variable is as defined in the specification. The present application also disclosed a nanoparticle composition comprising the compound or a salt or a stereoisomer thereof, and the use of the nanoparticle composition for delivering active agents.